Y Baran1, S Zencir, Z Cakir, E Ozturk, Z Topcu. 1. Department of Molecular Biology and Genetics, Faculty of Sciences, Izmir Institute of Technology, Izmir, Turkey.
Abstract
WHAT IS KNOWN AND OBJECTIVE: Imatinib is a specific BCR/ABL inhibitor, commonly used for the treatment of chronic myeloid leukaemia (CML), a hematological malignancy resulting from a chromosomal translocation that generates the BCR/ABL fusion protein. Recent studies showed that the imatinib has cytotoxic and apoptotic effects on many BCR/ABL-negative cancers. Numerous compounds with cytotoxic potential exert their functions by interfering with the DNA topoisomerase. In this study, we examined the effects of imatinib on tumour cell-killing in relation to DNA topoisomerase enzyme inhibition. METHODS: We determined the cytotoxicity by cell proliferation assay (XTT; tetrazolium hydroxide), using the human K562 CML cells, and loss of mitochondrial membrane potential by monitoring the changes in caspase-3 enzyme activity. Type I and II topoisomerase activities were measured by supercoiled plasmid relaxation and minicircle DNA decatenation assays respectively. RESULTS AND DISCUSSION: Imatinib-induced apoptosis and inhibited cell proliferation in a dose-dependent manner. We also found that the imatinib was effective in both type I and type II topoisomerase reactions to a varying degree between 94% and 7% for the concentration range of 1 mm-0.02 mm in a dose-dependent manner. WHAT IS NEW AND CONCLUSION: Our results suggest that the inhibition of topoisomerases may be a significant factor in imatinib-induced apoptosis in CML.
WHAT IS KNOWN AND OBJECTIVE:Imatinib is a specific BCR/ABL inhibitor, commonly used for the treatment of chronic myeloid leukaemia (CML), a hematological malignancy resulting from a chromosomal translocation that generates the BCR/ABL fusion protein. Recent studies showed that the imatinib has cytotoxic and apoptotic effects on many BCR/ABL-negative cancers. Numerous compounds with cytotoxic potential exert their functions by interfering with the DNA topoisomerase. In this study, we examined the effects of imatinib on tumour cell-killing in relation to DNA topoisomerase enzyme inhibition. METHODS: We determined the cytotoxicity by cell proliferation assay (XTT; tetrazolium hydroxide), using the human K562 CML cells, and loss of mitochondrial membrane potential by monitoring the changes in caspase-3 enzyme activity. Type I and II topoisomerase activities were measured by supercoiled plasmid relaxation and minicircle DNA decatenation assays respectively. RESULTS AND DISCUSSION: Imatinib-induced apoptosis and inhibited cell proliferation in a dose-dependent manner. We also found that the imatinib was effective in both type I and type II topoisomerase reactions to a varying degree between 94% and 7% for the concentration range of 1 mm-0.02 mm in a dose-dependent manner. WHAT IS NEW AND CONCLUSION: Our results suggest that the inhibition of topoisomerases may be a significant factor in imatinib-induced apoptosis in CML.
Authors: Hong Jun Kim; Sun Kyung Baek; Chi Hoon Maeng; Si-Young Kim; Tae Sung Park; Jae Joon Han Journal: World J Clin Cases Date: 2020-04-06 Impact factor: 1.337
Authors: Hemant Kulkarni; Harald H H Göring; Vincent Diego; Shelley Cole; Ken R Walder; Greg R Collier; John Blangero; Melanie A Carless Journal: BMC Med Genomics Date: 2012-08-23 Impact factor: 3.063